281 results about "Adverse effect" patented technology

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.

The invention relates to a traditional Chinese medicine composition for treating allergic dermatitis. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of fried coix seeds, 5-35 parts of concha margaritifera, 1-30 parts of honeysuckle stems, 1-30 parts of smoked plums, 1-30 parts of fructus liquidambaris, 1-25 parts of fructus forsythiae, 1-25 parts of radix paeoniae rubra, 1-25 parts of raw sanguisorba officinalis, 1-25 parts of radix glehniae, 1-25 parts of radix ophiopogonis and 1-25 parts of raw radix polygonati officinalis. 1-25 parts by weight of talc and 1-25 parts by weight of lophatherum gracile. The traditional Chinese medicine composition has the effects of clearing heat, cooling blood without bitter cold, dispelling wind, eliminating dampness without hurting stomach, detoxifying, relieving itching and nourishing yin, is safe in clinical use, and has no adverse effect on liver and kidney.

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.

The invention discloses a tumor radiotherapy non-irradiation area protection device, and relates to the cervical cancer radiotherapy protection field, and the tumor radiotherapy non-irradiation area protection device comprises a mounting frame, and the interior of the mounting frame is fixedly connected with a first telescopic driving member. The first moving mechanism and the second moving mechanism can respectively drive the moving frame and the adjusting plate to move back and forth and left and right, so that the through hole is accurately positioned to the radiotherapy position of the cervical cancer patient. The first rotation driving piece can drive the adjusting lead plate to rotate, so that the adjusting holes with proper sizes are aligned with cancer cells. The blocking adjusting mechanism further optimizes protection, and when a gap exists between the adjusting hole and the cancer cells, the driving mechanism drives the transmission ring to rotate, so that the second telescopic driving piece drives the pushing block to push the lead block plate to move, and the gap is filled. Thus, the first lead plate, the second lead plate and the adjusting lead plate act together to ensure that radiotherapy rays irradiate cancer cells only through the adjusting holes, so that the rays are effectively prevented from damaging surrounding healthy tissues, and adverse effects of radiotherapy on patients are reduced.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of plant polypeptide. The schisandra chinensis active polypeptide is prepared by carrying out enzymolysis reaction on schisandra chinensis protein. The schisandra chinensis active polypeptide can effectively inhibit the activity of angiotensin converting enzyme (ACE), so that the schisandra chinensis active polypeptide can be used as an ACE inhibitor to reduce blood pressure. The plant extract disclosed by the invention not only has the functions of high-efficiency antihypertensive effect, no toxicity, no side effect and the like, but also has the advantages of simplicity in preparation, easiness in absorption and the like, and avoids adverse effects of side effects of traditional chemical medicines on human bodies.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application provides a Guizhou Rhamnus skin wound healing ointment and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions. The ointment comprises Guizhou Rhamnus concentrated extract and base excipients. The ointment has the functions of promoting skin wound healing, preventing swelling and pain, preventing infection and scar, reducing swelling and pain, removing blood stasis and promoting tissue regeneration, dredging channels and activating collaterals, and healthy skin tissue. The active ingredients of traditional Chinese medicine have the advantages of rapid healing and repair, obvious swelling and pain relief, delicate ointment texture, easy absorption by the skin, high safety, good stability, wide source of raw materials, easy collection, simple preparation process, batch processing, no toxic side effects on the health of production personnel, and no adverse effects on the environment.

The invention discloses a herbal medicine composition and application thereof. The herbal medicine composition comprises the following components in percentage by mass: 5%-85% of an extract of Indian ginseng, 5%-85% of an extract of rhodiola rosea, 5%-85% of an extract of melissa officinalis and 5%-85% of an extract of holy basil. The herbal composition is a natural composition that effectively supports mental health while minimizing adverse effects and promoting overall health; in particular, the herbal composition can achieve effects including "coordinated regulation of multiple neurotransmitter systems", "multi-target regulation of an HPA axis", "coordinated enhancement of an antioxidant system", "coordinated promotion of neuronutrition and neuroplasticity", "a synergistic effect of inflammation regulation", and "a synergistic effect of gene expression regulation".

The application discloses an arteriovenous fistula system, and relates to the technical field of medical devices, which comprises a fistula catheter, a handle, a power transmission line and a power output controller. The application makes the operation of the fistula catheter head more convenient, realizes accurate detection of the relative displacement amount of the head electrode, makes the fistula catheter head not loosen even if the external force disappears after being closed, improves the structure of the heating electrode, and makes the size and angle of the fistula not adversely affect the blood flow. The application adds blood flow, blood pressure, temperature and other sensors in the fistula catheter, cooperates with the control function of the power output controller, realizes accurate detection of the opening and closing state of the fistula catheter head, automatic detection of the arteriovenous vessel wall capture, safe output of energy and heating control of the fistula catheter head electrode. The application is more beneficial to the operation of doctors in clinical use and can obtain better fistula effect.

The invention discloses a composition for improving adverse effects of chemotherapy as well as a preparation method, application and a product of the composition, and particularly relates to the technical field of medicines. The composition comprises the following raw materials: tortoise, soft-shelled turtle, antler, sea cucumber, fructus amomi, pericarpium citri reticulatae and hawthorn. Alkaline protease and flavourzyme are adopted for enzymolysis, and the obtained composition can remarkably reduce the tumor volume of tumor-bearing animals, increase the bone marrow DNA content of chemotherapy animals and remarkably increase the number of white blood cells and the number of red blood cells in peripheral blood of the chemotherapy animals. The composition disclosed by the invention is used for preparing related products for improving the adverse effects of chemotherapy, and the prepared products are easy to absorb and have a remarkable improvement effect on the adverse effects of chemotherapy.

A C-terminal fragment of insulin-like growth factor binding protein 2 (IGFBP2) containing 3 cysteine residues has been shown to spontaneously self-assemble into nanotube (NT) structures. These NTs can encapsulate drugs during the assembly process and then deliver their cargo intracellularly following binding to interns and endocytosis. The integrin-dependence of this process is mediated by the presence of a naturally occurring RGD motif within the peptide sequence. A particular advantage of such NTs is that by encapsulating small molecule drugs, tissues are protected from their adverse effects. Here, the use of NTs to deliver small drugs and biologics across the blood-brain barrier (BBB) by penetrating the CNS and delivering their cargo is described.

The invention discloses application of a compound DBP-64 in preparation of a medicine for preventing and treating magnaporthe oryzae, belongs to the field of prevention and treatment of plant fungal diseases, and finds that the compound DBP-64 has a remarkable effect on inhibiting the magnaporthe oryzae or / and other pathogenic fungi, can effectively inhibit the pathogenicity of magnaporthe oryzae spores in a concentration range of 3-50 ppm, and can be used for preparing a medicine for preventing and treating the magnaporthe oryzae. Especially, 50 ppm of the compound DBP-64 can completely prevent and treat rice blast, and the application method is simple. The compound DBP-64 and a magnaporthe oryzae spore liquid are mixed and sprayed for 0 hour, so that a certain prevention and treatment effect is achieved, and the compound DBP-64 can be used as a protection medicament in the early stage of magnaporthe oryzae infection and has a better effect; moreover, the rice sprayed with the compound is good in growth situation and free of obvious adverse effects, which indicates that the compound is safe to the rice and has practical significance in preventing rice blast.

Described are synthetic compounds having anti-inflammatory properties and optionally analgesic properties. These compounds are derivatives of FDA-approved anti-inflammatory, such as ibuprofen and indomethacin, and can be formed using reactions under microwave irradiation. Generally, the compounds contains a moiety of the parent drug, a triazolyl heterocycle, and a substituted or unsubstituted aryl group. In some forms, the compounds show anti-inflammatory properties and optionally analgesic properties with similar or higher efficiencies compared with their respective parent drugs, with additional advantages including no or reduced adverse effects (e.g., without ulcerogenic liability in the gastric) and / or selective inhibition of COX-2 over COX-1. Pharmaceutical compositions suitable for the delivery of the compounds to a subject in need thereof are disclosed. The pharmaceutical formulation can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. Methods for preventing or treating an inflammatory disease or disorder in a subject are also disclosed.

Methods for using bioadhesive and stearic interactions specific to copolymers with at least two moieties, to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology. Multifunctional copolymers have bioadhesive properties driven by electrostatic and hydrophobic interactions and passivation though hydrophilic moieties. These copolymers are useful for reducing rates of viral infectivity in target cells, and in reducing host morbidity and can be coforulated. These copolymers are useful for reducing ADC related, oncology therapy related, preservative related, systemic- pharmaceutical-therapy related, and / or topical ophthalmic active-pharmaceutical- ingredient related toxicity which can be manifest as a corneal epithelial toxicity. Methods for enhancing efficacy through coformulations with mucopenetration enhancing technologies and in coformulations with other actives that inhibit macropinocytosis allow for increasing efficacy in patient treatment approaches described herein. Coformulations with other actives ingredient will have therapeutic utility and prove beneficial in various settings. Formulations of these multifunctional copolymers for topical ophthalmic use are safe and well tolerated. Epithelial cells and the ocular surface including limbal stem cell and precursor corneal epithelial cells are treated with these copolymers to confer utility and patient benefit. Corneal nerves are similarly protected and corneal nerve cell damage is mitigated. Contact lenses provide an alternative method for delivering protective copolymers to the eye in these settings.

The present application relates to the field of pharmaceutical preparations, in particular to 5-amino-ketoglutaric acid metal complex, liposome and preparation method thereof. The 5-amino-ketoglutaric acid metal complex of the present application is formed by 5-amino-ketoglutaric acid and metal ion through coordination bond, and is a photosensitizer which can be used for photodynamic therapy of tumor. After ALA forms complex with metal ion, the reaction activity of amino and ketone groups in ALA molecule is reduced, the adverse influence of external environment on the molecule is delayed, and the stability is enhanced. Moreover, the co-aggregation of ALA and copper ion (or iron ion) to target tissue, the two means of ALA photodynamic therapy of tumor and copper (iron) ion promoting tumor cell apoptosis play drug efficacy, and have synergistic anti-tumor effect. The present application further provides liposome loaded with 5-amino-ketoglutaric acid metal complex, and preparation containing 5-amino-ketoglutaric acid metal complex or liposome.

Described herein are compositions and methods for therapeutic delivery using an engineered viral vector. The engineered viral vector provided herein can improve therapeutic delivery, increase targeting efficiency, and decrease off-targeting or adverse effects.

Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.

The utility model relates to medical nursing instrument technical field, concretely relates to a three -fold turning over mattress structure, the mattress forms left part board, middle part board and right part board along its width direction, the left part board, middle part board and right part board are hinged through the hinge piece, are used for the board body overturning along the mattress length direction, be equipped with angle controller on the hinge piece, be used for adjusting the overturning angle of board body, the utility model discloses the cooperation of hinge piece and angle controller realizes the accurate adjustment of each board body overturning angle, reduces the adverse effect force to the skin in the process of turning over, satisfies the diversified body position change demand simultaneously.

The application discloses application of a miR-8069 inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-8069 in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-8069 can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a model of cerebral stroke in vitro in research. The miR-8069 inhibitor disclosed by the application is used for preparing a medicine for treating cerebral stroke, and the nucleotide sequence is as follows: ACCGCCGACCGCCCCCAACCAUCC.

The utility model discloses a blood seepage prevention device for hemodialysis nursing, which belongs to the technical field of medical instruments and comprises a first arc-shaped plate and a second arc-shaped plate, and two connecting blocks are fixedly connected to two sides of the outer parts of adjacent ends of the first arc-shaped plate and the second arc-shaped plate. After hexagon bolts outside a first limiting rod and a second limiting rod are taken down, angle adjustment fitting the bending degree of the upper limbs is conducted through a connecting block and a hinge rod, after the angle comfortable for a patient is achieved through adjustment, the hexagon bolts outside the first limiting rod and the second limiting rod are screwed into new corresponding threaded holes, and fixing is completed; the device has a good adjusting and supporting effect, a worker can conveniently assist a patient in small-amplitude angle adjustment of the upper limbs, the limp and numb uncomfortable state is relieved, stable blood flowing is ensured, the adverse effect on the dialysis effect is reduced, and the workload of the worker is prevented from being increased.

The p300 inhibitor specifically regulates the expression of genes that induce fibrosis, thereby acting only on fibrotic tissues and reducing the risk of adverse effects on normal tissues. Because the inhibitor blocks multiple fibrotic signaling pathways, it may be effective for fibrosis in various organs such as the liver, lungs, and kidneys. In addition, by modulating gene expression, the inhibitor has the potential to address the fundamental cause of the fibrotic process. The present invention is characterized in that bronopol is first identified as a specific example of such a p300 inhibitor. In particular, bronopol is an FDA-approved drug with established safety, and therefore is expected to reduce the time and cost required for conducting clinical trials.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and / or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

The invention belongs to the technical field of biomedical materials, and particularly discloses a zinc-based alloy guided bone regeneration barrier membrane as well as a preparation method and application thereof. Based on Zn, Cu, Li and Mg element selection, by reasonably setting the proportion of each alloy component, the degradable zinc-based guided bone regeneration membrane which has excellent biocompatibility, proper degradation speed, mechanical property, bone healing promotion, bone regeneration capability and antibacterial property is preferably selected; and meanwhile, adverse effects on bone regeneration caused by over-high degradation rate of other metal films such as magnesium alloy and hydrogen generated in the release process of the metal films are also avoided. The Zn-2Cu-0.8 Li-0.2 Mg alloy film is optimally selected from the comprehensive aspects of degradation speed, mechanical property, biocompatibility, guided bone regeneration performance, antibacterial performance and the like, and a high-quality guided bone regeneration material is provided for repairing bone defects such as alveolar bones.

The present application relates to reducing the adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, astrocyte loss, or white matter loss, in the brain of a subject. The present application also relates to rejuvenating glial progenitor cells or their progeny, or enhancing the developmental potential of glial progenitor cells or their progeny.

The invention relates to a composition comprising N-acetylcysteine (NAC) for use in the prevention and / or treatment of at least one adverse effect of a chemotherapy in the treatment of cancer. It is characterized in that it further comprises vitamin B12 and / or a combination of vitamins B1, B2 and B3. The invention more particularly relates to the use of said composition for the prevention and / or treatment of chemo-induced nociceptive and / or neuropathic pain.

The invention relates to a medicinal and edible compound extract for improving myelosuppression of a tumor patient after chemotherapy, and a preparation method and application of the medicinal and edible compound extract. The compound extract is extracted from a composition at least comprising the following raw material medicines in parts by weight: 0.9-10 parts of tricholoma matsutake, 0.9-10 parts of mulberry and 0.5-10 parts of rhizoma polygonati. The raw material medicine composition further comprises the following raw material medicines in parts by weight: 0.7-10 parts of longan, 0.5-10 parts of pericarpium citri reticulatae, 0.5-10 parts of scorched hawthorn fruit, 0.5-10 parts of fructus amomi, 1.1-10 parts of cordyceps sinensis rice flour and 2.5-15 parts of rice peptide. The selected raw material medicines are all medicinal and edible components, do not cause adverse effects on liver and kidney functions and gastrointestinal tracts of eaters, and are high in safety and high in patient acceptance degree. Effect verification results show that the mulberry compound extract has an improvement effect on the side effect of bone marrow suppression of tumor patients, especially in the early stage, no related adverse reaction is found, and a safe and effective treatment choice is provided for bone marrow suppression.

The application discloses an application of a miR-4680-3p inhibitor and belongs to the technical field of biological medicines.The inventor of the application finds that the expression of miR-4680-3p in the plasma of IS patients is abnormally increased in the research on the pathogenesis of IS, and through further cell experiments, it is found that inhibiting the expression of miR-4680-3p can effectively improve the adverse effects of OGD / R treatment on cell viability, apoptosis and ROS, and has a significant therapeutic effect on IS. Cell damage induced by OGD / R is often used as a classic model of cerebral apoplexy in vitro in research. The miR-4680-3p inhibitor disclosed by the application is used for preparing a medicine for treating ischemic apoplexy, and the nucleotide sequence of the miR-4680-3p inhibitor is as follows: UAACAACUCUUACAAUUCAGA.

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine / threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.